Sana Biotechnology (SANA)
NASDAQ:SANA
Want to see SANA full AI Analyst Report?
Sc262
Large B-Cell Lymphoma, Non Hodgkin's Lymphoma
Phase I
Recruiting
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Feb 22, 2024
―
Sc291
Systemic Lupus Erythematosus, Lupus Erythematosus, Sle (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Phase I
Recruiting
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
Feb 12, 2024
―
Sc291
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Phase I
Active Not Recruiting
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Apr 28, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Sana Biotechnology (SANA) have in its pipeline
SANA is currently developing the following drugs: Sc262, Sc291, Sc291. These drug candidates are in various stages of clinical development as the company works toward FDA approval.